Overview

A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan

Status:
Completed
Trial end date:
2020-04-21
Target enrollment:
Participant gender:
Summary
This study is designed to investigate the efficacy, safety and pharmacokinetics of adalimumab in subjects in Japan with active ulcer(s) due to Pyoderma Gangrenosum (PG).
Phase:
Phase 3
Details
Lead Sponsor:
AbbVie
Treatments:
Adalimumab